{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:12:40Z","timestamp":1793725960013,"version":"4.6.1"},"reference-count":136,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Peripheral artery disease (PAD) is a prevalent manifestation of systemic atherosclerosis, associated with elevated risks of major adverse cardiovascular events (MACE) and major adverse limb events (MALE). Despite its clinical significance, PAD remains underdiagnosed and undertreated, reflecting substantial gaps in guideline implementation. This review highlights advances in the medical management of PAD, focusing on strategies targeting the metabolic, lipid, immuno-inflammatory, and thrombotic drivers of disease to improve cardiovascular and limb outcomes. Optimal management requires intensive, multifaceted approaches that integrate lifestyle modification (including smoking cessation, a healthy diet, and physical activity), risk factor control, and pharmacologic interventions. Dual pathway antithrombotic therapy with low-dose rivaroxaban and aspirin has emerged as a superior strategy to mitigate both cardiovascular and limb events in patients with high ischaemic risk and non-high bleeding risk. Statins are the first-line lipid-lowering therapy for all patients with PAD, and if low-density lipoprotein cholesterol (LDL-C) goals are not achieved with maximally tolerated doses, adjunctive agents\u2014such as ezetimibe, bempedoic acid, and proprotein convertase subtilisin\/kexin type 9 inhibitors (PCSK9i)\u2014should be added. Novel antidiabetic agents, particularly glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is), confer cardiovascular and renal benefits independent of glycaemic control, with emerging data suggesting that GLP-1 RAs may also reduce limb events. To date, semaglutide remains the only anti-obesity pharmacotherapy that has been demonstrated to reduce cardiovascular events in high-risk patients with overweight or obesity in the absence of diabetes. We propose a phenotype-driven approach to enable refined risk stratification across the PAD spectrum, supporting individualized and, when needed, more intensive management.<\/jats:p>","DOI":"10.1093\/eurheartj\/ehag516","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T13:25:37Z","timestamp":1784294737000},"source":"Crossref","is-referenced-by-count":3,"title":["Peripheral artery disease: advances in medical therapy"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3271-7316","authenticated-orcid":false,"given":"Fernando","family":"Garagoli","sequence":"first","affiliation":[{"name":"Cardiology Department, Hospital Italiano de Buenos Aires , Buenos Aires ,","place":["Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3091-3735","authenticated-orcid":false,"given":"Leandro","family":"Slipczuk","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Montefiore Health System\/Albert Einstein College of Medicine , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9071-3287","authenticated-orcid":false,"given":"Michael D","family":"Shapiro","sequence":"additional","affiliation":[{"name":"Center for Prevention of Cardiovascular Disease, Department of Cardiovascular Medicine, Wake Forest University School of Medicine , Winston-Salem, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9860-3584","authenticated-orcid":false,"given":"Marc P","family":"Bonaca","sequence":"additional","affiliation":[{"name":"CPC Clinical Research , Aurora, CO ,","place":["USA"]},{"name":"Department of Medicine, University of Colorado , Aurora, CO ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1278-6245","authenticated-orcid":false,"given":"Deepak L","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai , 1 Gustave Levy Place, Box 1030, New York, NY, 10029 \u00a0","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"2026071709145309800_ehag516-B1","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41572-025-00651-0","article-title":"Peripheral artery disease","volume":"11","author":"Aboyans","year":"2025","journal-title":"Nat Rev Dis Primers"},{"key":"2026071709145309800_ehag516-B2","doi-asserted-by":"publisher","first-page":"e171","DOI":"10.1161\/CIR.0000000000001005","article-title":"Lower extremity peripheral artery disease: contemporary epidemiology, management gaps, and future directions: a scientific statement from the American Heart Association","volume":"144","author":"Criqui","year":"2021","journal-title":"Circulation"},{"key":"2026071709145309800_ehag516-B3","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2023.4213","article-title":"Trends in US adult smoking prevalence, 2011 to 2022","volume":"4","author":"Meza","year":"2023","journal-title":"JAMA Health Forum"},{"key":"2026071709145309800_ehag516-B4","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1186\/s12877-025-06228-6","article-title":"Trends of the burden, risk factors, and future projections of peripheral artery disease in the elderly","volume":"25","author":"Chen","year":"2025","journal-title":"BMC Geriatr"},{"key":"2026071709145309800_ehag516-B5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.atherosclerosis.2022.04.029","article-title":"Comparative mortality according to peripheral artery disease and coronary heart disease\/stroke in the United States","volume":"354","author":"Matsushita","year":"2022","journal-title":"Atherosclerosis"},{"key":"2026071709145309800_ehag516-B6","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1001\/jama.295.2.180","article-title":"International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis","volume":"295","author":"Bhatt","year":"2006","journal-title":"JAMA"},{"key":"2026071709145309800_ehag516-B7","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1001\/jama.286.11.1317","article-title":"Peripheral arterial disease detection, awareness, and treatment in primary care","volume":"286","author":"Hirsch","year":"2001","journal-title":"JAMA"},{"key":"2026071709145309800_ehag516-B8","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/j.jacc.2017.02.064","article-title":"Underuse of prevention and lifestyle counseling in patients with peripheral artery disease","volume":"69","author":"Berger","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026071709145309800_ehag516-B9","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1093\/eurheartj\/ehae179","article-title":"2024 ESC guidelines for the management of peripheral arterial and aortic diseases","volume":"45","author":"Mazzolai","year":"2024","journal-title":"Eur Heart J"},{"key":"2026071709145309800_ehag516-B10","doi-asserted-by":"publisher","first-page":"e1313","DOI":"10.1161\/CIR.0000000000001251","article-title":"2024 ACC\/AHA\/AACVPR\/APMA\/ABC\/SCAI\/SVM\/SVN\/SVS\/SIR\/VESS guideline for the management of lower extremity peripheral artery disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Gornik","year":"2024","journal-title":"Circulation"},{"key":"2026071709145309800_ehag516-B11","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.ejvs.2018.01.019","article-title":"Ten year mortality in different peripheral arterial disease stages: a population based observational study on outcome","volume":"55","author":"Sartipy","year":"2018","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"2026071709145309800_ehag516-B12","doi-asserted-by":"publisher","first-page":"413","DOI":"10.23736\/S2724-5683.21.05704-5","article-title":"Additive prognosis of clinical presentation in revascularized peripheral arterial disease patients","volume":"70","author":"Garagoli","year":"2022","journal-title":"Minerva Cardiol Angiol"},{"key":"2026071709145309800_ehag516-B13","doi-asserted-by":"publisher","first-page":"e1154","DOI":"10.1161\/CIR.0000000000001423","article-title":"2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"153","author":"Writing Committee Members","year":"2026","journal-title":"Circulation"},{"key":"2026071709145309800_ehag516-B14","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1097\/MOL.0000000000000998","article-title":"Lipoprotein(a) and peripheral artery disease: contemporary evidence and therapeutic advances","volume":"36","author":"Thanigaimani","year":"2025","journal-title":"Curr Opin Lipidol"},{"key":"2026071709145309800_ehag516-B15","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwaf475","article-title":"Association between lipoprotein(a) and cardiovascular events in patients with peripheral artery disease: the Mass General Brigham Lp(a) registry","author":"McClintick","year":"2025","journal-title":"Eur J Prev Cardiol"},{"key":"2026071709145309800_ehag516-B16","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1080\/10408363.2025.2512472","article-title":"Association of inflammatory biomarkers with morbidity and mortality risk in patients with peripheral artery disease: a systematic review and -meta-analysis","volume":"62","author":"Frag\u00e3o-Marques","year":"2025","journal-title":"Crit Rev Clin Lab Sci"},{"key":"2026071709145309800_ehag516-B17","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1154708","article-title":"A modern day perspective on smoking in peripheral artery disease","volume":"10","author":"Behrooz","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"2026071709145309800_ehag516-B18","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.jvs.2017.10.091","article-title":"The impact of current smoking on outcomes after infrainguinal bypass for claudication","volume":"68","author":"Kalbaugh","year":"2018","journal-title":"J Vasc Surg"},{"key":"2026071709145309800_ehag516-B19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/jamacardio.2021.3979","article-title":"Association of smoking with postprocedural complications following open and endovascular interventions for intermittent claudication","volume":"7","author":"Reitz","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2026071709145309800_ehag516-B20","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/j.jvs.2014.08.064","article-title":"Smoking cessation is associated with decreased mortality and improved amputation-free survival among patients with symptomatic peripheral artery disease","volume":"60","author":"Armstrong","year":"2014","journal-title":"J Vasc Surg"},{"key":"2026071709145309800_ehag516-B21","doi-asserted-by":"publisher","first-page":"958","DOI":"10.12968\/bjon.2023.32.20.958","article-title":"Smoking cessation: why is it a persistent problem in patients with peripheral artery disease?","volume":"32","author":"Lampridou","year":"2023","journal-title":"Br J Nurs"},{"key":"2026071709145309800_ehag516-B22","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.pcad.2025.07.007","article-title":"How to facilitate smoking cessation","volume":"92","author":"Colivicchi","year":"2025","journal-title":"Prog Cardiovasc Dis"},{"key":"2026071709145309800_ehag516-B23","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1001\/jama.2013.280618","article-title":"Association of Mediterranean diet with peripheral artery disease: the PREDIMED randomized trial","volume":"311","author":"Ruiz-Canela","year":"2014","journal-title":"JAMA"},{"key":"2026071709145309800_ehag516-B24","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s10654-025-01232-x","article-title":"Partial substitution of red or processed meat with plant-based foods and the risk of cardiovascular disease","volume":"40","author":"Simojoki","year":"2025","journal-title":"Eur J Epidemiol"},{"key":"2026071709145309800_ehag516-B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.100948","article-title":"Implications of food ultra-processing on cardiovascular risk considering plant origin foods: an analysis of the UK Biobank cohort","volume":"43","author":"Rauber","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"2026071709145309800_ehag516-B26","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwaf611","article-title":"Feeding vascular health: role of nutrition in peripheral artery disease prevention and management","author":"Butler","year":"2025","journal-title":"Eur J Prev Cardiol"},{"key":"2026071709145309800_ehag516-B27","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1136\/bjsports-2020-102955","article-title":"World Health Organization 2020 guidelines on physical activity and sedentary behaviour","volume":"54","author":"Bull","year":"2020","journal-title":"Br J Sports Med"},{"key":"2026071709145309800_ehag516-B28","doi-asserted-by":"publisher","first-page":"e700","DOI":"10.1161\/CIR.0000000000000727","article-title":"Implementation of supervised exercise therapy for patients with symptomatic peripheral artery disease: a science advisory from the American Heart Association","volume":"140","author":"Treat-Jacobson","year":"2019","journal-title":"Circulation"},{"key":"2026071709145309800_ehag516-B29","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.pcad.2024.02.003","article-title":"Update to the 2016 American Heart Association cardiorespiratory fitness statement","volume":"83","author":"Ross","year":"2024","journal-title":"Prog Cardiovasc Dis"},{"key":"2026071709145309800_ehag516-B30","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.avsg.2021.01.076","article-title":"Sarcopenia as a prognostic factor in peripheral arterial disease: descriptive review","volume":"74","author":"Ferreira","year":"2021","journal-title":"Ann Vasc Surg"},{"key":"2026071709145309800_ehag516-B31","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.jacc.2024.06.027","article-title":"Antithrombotic strategies for patients with peripheral artery disease: JACC Scientific Statement","volume":"84","author":"Bonaca","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026071709145309800_ehag516-B32","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1157\/13109651","article-title":"[Peripheral artery disease: pathophysiology, diagnosis and treatment]","volume":"60","author":"Serrano Hernando","year":"2007","journal-title":"Rev Esp Cardiol"},{"key":"2026071709145309800_ehag516-B33","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1161\/ATVBAHA.114.304764","article-title":"Prevalence of nonatheromatous lesions in peripheral arterial disease","volume":"35","author":"O\u2019Neill","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026071709145309800_ehag516-B34","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1161\/CIRCULATIONAHA.107.736108","article-title":"Asymptomatic peripheral arterial disease is associated with more adverse lower extremity characteristics than intermittent claudication","volume":"117","author":"McDermott","year":"2008","journal-title":"Circulation"},{"key":"2026071709145309800_ehag516-B35","doi-asserted-by":"publisher","first-page":"873","DOI":"10.7326\/0003-4819-136-12-200206180-00008","article-title":"The ankle brachial index is associated with leg function and physical activity: the Walking and Leg Circulation Study","volume":"136","author":"McDermott","year":"2002","journal-title":"Ann Intern Med"},{"key":"2026071709145309800_ehag516-B36","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.a1840","article-title":"The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease","volume":"337","author":"Belch","year":"2008","journal-title":"BMJ"},{"key":"2026071709145309800_ehag516-B37","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1001\/jama.2010.221","article-title":"Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial","volume":"303","author":"Fowkes","year":"2010","journal-title":"JAMA"},{"key":"2026071709145309800_ehag516-B38","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S0140-6736(25)01562-4","article-title":"Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis","volume":"406","author":"Valgimigli","year":"2025","journal-title":"Lancet"},{"key":"2026071709145309800_ehag516-B39","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/s0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee","volume":"348","author":"CAPRIE Steering Committee","year":"1996","journal-title":"Lancet"},{"key":"2026071709145309800_ehag516-B40","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1001\/jamacardio.2020.4390","article-title":"Rivaroxaban and aspirin in patients with symptomatic lower extremity peripheral artery disease: a subanalysis of the COMPASS Randomized Clinical Trial","volume":"6","author":"Kaplovitch","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2026071709145309800_ehag516-B41","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.jacc.2018.06.041","article-title":"Major adverse limb events and 1-year outcomes after peripheral artery revascularization","volume":"72","author":"Hess","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026071709145309800_ehag516-B42","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","article-title":"Rivaroxaban in peripheral artery disease after revascularization","volume":"382","author":"Bonaca","year":"2020","journal-title":"N Engl J Med"},{"key":"2026071709145309800_ehag516-B43","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1161\/CIRCULATIONAHA.120.050465","article-title":"Rivaroxaban and aspirin in peripheral artery disease lower extremity revascularization: impact of concomitant clopidogrel on efficacy and safety","volume":"142","author":"Hiatt","year":"2020","journal-title":"Circulation"},{"key":"2026071709145309800_ehag516-B44","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 focused update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias","volume":"46","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"key":"2026071709145309800_ehag516-B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2024.100645","article-title":"Atherosclerotic coronary plaque regression from lipid-lowering therapies: a meta-analysis and meta-regression","volume":"18","author":"Rivera","year":"2024","journal-title":"Am J Prev Cardiol"},{"key":"2026071709145309800_ehag516-B46","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.5551\/jat.RV22024","article-title":"Lipid-lowering therapy and coronary plaque regression","volume":"31","author":"Ueki","year":"2024","journal-title":"J Atheroscler Thromb"},{"key":"2026071709145309800_ehag516-B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2024.176338","article-title":"Hegemony of inflammation in atherosclerosis and coronary artery disease","volume":"966","author":"Attiq","year":"2024","journal-title":"Eur J Pharmacol"},{"key":"2026071709145309800_ehag516-B48","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.jvs.2006.12.054","article-title":"Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions","volume":"45","author":"Heart Protection Study Collaborative Group","year":"2007","journal-title":"J Vasc Surg"},{"key":"2026071709145309800_ehag516-B49","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/S2213-8587(18)30290-0","article-title":"Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial","volume":"6","author":"Bonaca","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026071709145309800_ehag516-B50","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jcmg.2025.01.005","article-title":"Effects of evolocumab on coronary plaque composition and microcalcification activity by coronary PET and CT angiography","volume":"18","author":"Han","year":"2025","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026071709145309800_ehag516-B51","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.71365","article-title":"Proprotein Convertase Subtilisin\/Kexin Type 9 (PCSK9) inhibitors as adjunct therapy to statins: a new frontier in cardiovascular risk reduction","volume":"16","author":"Lamia","year":"2024","journal-title":"Cureus"},{"key":"2026071709145309800_ehag516-B52","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","article-title":"Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)","volume":"137","author":"Bonaca","year":"2018","journal-title":"Circulation"},{"key":"2026071709145309800_ehag516-B53","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1161\/CIRCULATIONAHA.120.046524","article-title":"Peripheral artery disease and venous thromboembolic events after acute coronary syndrome: role of lipoprotein(a) and modification by alirocumab: prespecified analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial","volume":"141","author":"Schwartz","year":"2020","journal-title":"Circulation"},{"key":"2026071709145309800_ehag516-B54","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1016\/j.jvs.2020.08.129","article-title":"The cost-effectiveness of intensive low-density lipoprotein cholesterol lowering in people with peripheral artery disease","volume":"73","author":"Nastasi","year":"2021","journal-title":"J Vasc Surg"},{"key":"2026071709145309800_ehag516-B55","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2514428","article-title":"Evolocumab in patients without a previous myocardial infarction or stroke","volume":"394","author":"Bohula","year":"2026","journal-title":"N Engl J Med"},{"key":"2026071709145309800_ehag516-B56","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1001\/jama.2026.3277","article-title":"Evolocumab to reduce first Major cardiovascular events in patients without known significant atherosclerosis and with diabetes: results from the VESALIUS-CV Trial","volume":"335","author":"Marston","year":"2026","journal-title":"JAMA"},{"key":"2026071709145309800_ehag516-B57","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/eurheartj\/ehac594","article-title":"Inclisiran and cardiovascular events: a patient-level analysis of phase III trials","volume":"44","author":"Ray","year":"2023","journal-title":"Eur Heart J"},{"key":"2026071709145309800_ehag516-B58","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s11883-022-01054-2","article-title":"Bempedoic acid: for whom and when","volume":"24","author":"Ruscica","year":"2022","journal-title":"Curr Atheroscler Rep"},{"key":"2026071709145309800_ehag516-B59","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"2026071709145309800_ehag516-B60","doi-asserted-by":"publisher","DOI":"10.1161\/circ.150.suppl_1.4139186","article-title":"Abstract 4139186: bempedoic acid and limb outcomes in statin-intolerant patients with peripheral artery disease","volume":"150","author":"Bonaca","year":"2024","journal-title":"Circulation"},{"key":"2026071709145309800_ehag516-B61","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"2026071709145309800_ehag516-B62","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1056\/NEJMoa2513032","article-title":"Fish-oil supplementation and cardiovascular events in patients receiving hemodialysis","volume":"394","author":"Lok","year":"2026","journal-title":"N Engl J Med"},{"key":"2026071709145309800_ehag516-B63","doi-asserted-by":"publisher","first-page":"3615","DOI":"10.2174\/1381612043382819","article-title":"Hypertension in peripheral arterial disease","volume":"10","author":"Clement","year":"2004","journal-title":"Curr Pharm Des"},{"key":"2026071709145309800_ehag516-B64","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"SPRINT Research Group","year":"2015","journal-title":"N Engl J Med"},{"key":"2026071709145309800_ehag516-B65","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1161\/01.cir.0000049640.46039.52","article-title":"Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes","volume":"107","author":"Mehler","year":"2003","journal-title":"Circulation"},{"key":"2026071709145309800_ehag516-B66","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3317\/jraas.2000.002","article-title":"The HOPE study (Heart Outcomes Prevention Evaluation)","volume":"1","author":"Sleight","year":"2000","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"2026071709145309800_ehag516-B67","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"ONTARGET Investigators","year":"2008","journal-title":"N Engl J Med"},{"key":"2026071709145309800_ehag516-B68","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1016\/j.jvs.2020.02.041","article-title":"Improved survival with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic limb-threatening ischemia","volume":"72","author":"Khan","year":"2020","journal-title":"J Vasc Surg"},{"key":"2026071709145309800_ehag516-B69","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.atherosclerosis.2013.09.037","article-title":"Meta-analysis of angiotensin converting enzyme inhibitors effect on walking ability and ankle brachial pressure index in patients with intermittent claudication","volume":"231","author":"Shahin","year":"2013","journal-title":"Atherosclerosis"},{"key":"2026071709145309800_ehag516-B70","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005508.pub3","article-title":"Beta blockers for peripheral arterial disease","volume":"2013","author":"Paravastu","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2026071709145309800_ehag516-B71","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1161\/HYPERTENSIONAHA.110.169169","article-title":"\u03b2-Blockers in patients with intermittent claudication and arterial hypertension: results from the nebivolol or metoprolol in arterial occlusive disease trial","volume":"58","author":"Espinola-Klein","year":"2011","journal-title":"Hypertension"},{"key":"2026071709145309800_ehag516-B72","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1093\/eurheartj\/eht142","article-title":"Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II","volume":"34","author":"Beckman","year":"2013","journal-title":"Eur Heart J"},{"key":"2026071709145309800_ehag516-B73","doi-asserted-by":"publisher","first-page":"3274","DOI":"10.1016\/j.jacc.2018.09.078","article-title":"Cardiovascular and limb outcomes in patients with diabetes and peripheral artery disease: the EUCLID Trial","volume":"72","author":"Low Wang","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026071709145309800_ehag516-B74","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"2026071709145309800_ehag516-B75","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Action to Control Cardiovascular Risk in Diabetes Study Group","year":"2008","journal-title":"N Engl J Med"},{"key":"2026071709145309800_ehag516-B76","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"ADVANCE Collaborative Group","year":"2008","journal-title":"N Engl J Med"},{"key":"2026071709145309800_ehag516-B77","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur Heart J"},{"key":"2026071709145309800_ehag516-B78","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2026071709145309800_ehag516-B79","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1161\/CIRCULATIONAHA.119.044775","article-title":"Dapagliflozin and cardiac, kidney, and limb outcomes in patients with and without peripheral artery disease in DECLARE-TIMI 58","volume":"142","author":"Bonaca","year":"2020","journal-title":"Circulation"},{"key":"2026071709145309800_ehag516-B80","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"2026071709145309800_ehag516-B81","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2026071709145309800_ehag516-B82","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0234065","article-title":"Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: a systematic review and meta-analysis","volume":"15","author":"Heyward","year":"2020","journal-title":"PLoS One"},{"key":"2026071709145309800_ehag516-B83","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2026071709145309800_ehag516-B84","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1056\/NEJMc1615712","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"376","author":"Cosmi","year":"2017","journal-title":"N Engl J Med"},{"key":"2026071709145309800_ehag516-B85","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1111\/dom.14700","article-title":"Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease","volume":"24","author":"Verma","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"2026071709145309800_ehag516-B86","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"2026071709145309800_ehag516-B87","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"key":"2026071709145309800_ehag516-B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.endien.2025.501562","article-title":"Effect of glucagon-like peptide-1 receptor agonists on the risk of major adverse limb events in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized clinical trials","volume":"72","author":"Garagoli","year":"2025","journal-title":"Endocrinol Diabetes Nutr (Engl Ed)"},{"key":"2026071709145309800_ehag516-B89","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","article-title":"Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes","volume":"392","author":"McGuire","year":"2025","journal-title":"N Engl J Med"},{"key":"2026071709145309800_ehag516-B90","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/S0140-6736(25)00509-4","article-title":"Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial","volume":"405","author":"Bonaca","year":"2025","journal-title":"Lancet"},{"key":"2026071709145309800_ehag516-B91","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17081036","article-title":"Emerging frontiers in GLP-1 therapeutics: a comprehensive evidence base (2025)","volume":"17","author":"Patel","year":"2025","journal-title":"Pharmaceutics"},{"key":"2026071709145309800_ehag516-B92","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"key":"2026071709145309800_ehag516-B93","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"2026071709145309800_ehag516-B94","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s12933-024-02325-9","article-title":"Challenges and opportunities in the management of type 2 diabetes in patients with lower extremity peripheral artery disease: a tailored diagnosis and treatment review","volume":"23","author":"Mah\u00e9","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"2026071709145309800_ehag516-B95","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1056\/NEJMoa2505928","article-title":"Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes","volume":"393","author":"Nicholls","year":"2025","journal-title":"N Engl J Med"},{"key":"2026071709145309800_ehag516-B96","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990\u20132019: update from the GBD 2019 study","volume":"76","author":"Roth","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026071709145309800_ehag516-B97","doi-asserted-by":"publisher","first-page":"4798","DOI":"10.3390\/ijms22094798","article-title":"Impact of obesity-induced inflammation on Cardiovascular Diseases (CVD)","volume":"22","author":"Battineni","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026071709145309800_ehag516-B98","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1007\/s13679-023-00510-7","article-title":"Obesity and peripheral artery disease: current evidence and controversies","volume":"12","author":"Lempesis","year":"2023","journal-title":"Curr Obes Rep"},{"key":"2026071709145309800_ehag516-B99","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.1038\/s41591-025-03765-w","article-title":"Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO)","volume":"31","author":"McGowan","year":"2025","journal-title":"Nat Med"},{"key":"2026071709145309800_ehag516-B100","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2026071709145309800_ehag516-B101","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"2026071709145309800_ehag516-B102","doi-asserted-by":"publisher","DOI":"10.1093\/ehjopen\/oeaf117","article-title":"Tirzepatide compared with semaglutide and 10-year cardiovascular disease risk reduction in obesity: analysis of the SURMOUNT-5 trial","volume":"5","author":"Mamas","year":"2025","journal-title":"Eur Heart J Open"},{"key":"2026071709145309800_ehag516-B103","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1001\/jama.2025.8408","article-title":"Management of peripheral artery disease","volume":"334","author":"Kansal","year":"2025","journal-title":"JAMA"},{"key":"2026071709145309800_ehag516-B104","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1161\/CIR.0000000000000623","article-title":"Optimal exercise programs for patients with peripheral artery disease: a scientific statement from the American Heart Association","volume":"139","author":"Treat-Jacobson","year":"2019","journal-title":"Circulation"},{"key":"2026071709145309800_ehag516-B105","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/s0002-9343(00)00569-6","article-title":"A comparison of cilostazol and pentoxifylline for treating intermittent claudication","volume":"109","author":"Dawson","year":"2000","journal-title":"Am J Med"},{"key":"2026071709145309800_ehag516-B106","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1177\/1358863X10361545","article-title":"A pooled analysis of the durability and predictors of treatment response of cilostazol in patients with intermittent claudication","volume":"15","author":"Pande","year":"2010","journal-title":"Vasc Med"},{"key":"2026071709145309800_ehag516-B107","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003748.pub4","article-title":"Cilostazol for intermittent claudication","volume":"2014","author":"Bedenis","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2026071709145309800_ehag516-B108","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s11886-024-02065-y","article-title":"Medical therapy for peripheral artery disease","volume":"26","author":"Canonico","year":"2024","journal-title":"Curr Cardiol Rep"},{"key":"2026071709145309800_ehag516-B109","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1177\/1534734619900415","article-title":"Quality of life in diabetic foot ulcer: associated factors and the impact of anxiety\/depression and adherence to self-care","volume":"19","author":"Polikandrioti","year":"2020","journal-title":"Int J Low Extrem Wounds"},{"key":"2026071709145309800_ehag516-B110","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1111\/iwj.12404","article-title":"The impact of foot ulceration and amputation on mortality in diabetic patients. I: from ulceration to death, a systematic review","volume":"13","author":"Jupiter","year":"2016","journal-title":"Int Wound J"},{"key":"2026071709145309800_ehag516-B111","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1056\/NEJMra1615439","article-title":"Diabetic foot ulcers and their recurrence","volume":"376","author":"Armstrong","year":"2017","journal-title":"N Engl J Med"},{"key":"2026071709145309800_ehag516-B112","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.diabres.2019.05.003","article-title":"Effectiveness of a theory-based foot care education program (3STEPFUN) in improving foot self-care behaviours and foot risk factors for ulceration in people with type 2 diabetes","volume":"152","author":"Nguyen","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"2026071709145309800_ehag516-B113","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/j.mayocp.2022.03.038","article-title":"Peripheral artery disease and subsequent risk of infectious disease in older individuals: the ARIC study","volume":"97","author":"Mok","year":"2022","journal-title":"Mayo Clin Proc"},{"key":"2026071709145309800_ehag516-B114","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1056\/NEJMoa041747","article-title":"Risk of myocardial infarction and stroke after acute infection or vaccination","volume":"351","author":"Smeeth","year":"2004","journal-title":"N Engl J Med"},{"key":"2026071709145309800_ehag516-B115","doi-asserted-by":"publisher","first-page":"3518","DOI":"10.1093\/eurheartj\/ehaf384","article-title":"Vaccination as a new form of cardiovascular prevention: a European Society of Cardiology clinical consensus statement","volume":"46","author":"Heidecker","year":"2025","journal-title":"Eur Heart J"},{"key":"2026071709145309800_ehag516-B116","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22073601","article-title":"The role of circulating biomarkers in peripheral arterial disease","volume":"22","author":"Saenz-Pipaon","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026071709145309800_ehag516-B117","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/j.jacc.2009.04.081","article-title":"The role of biomarkers and genetics in peripheral arterial disease","volume":"54","author":"McDermott","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026071709145309800_ehag516-B118","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"2026071709145309800_ehag516-B119","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"2026071709145309800_ehag516-B120","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N Engl J Med"},{"key":"2026071709145309800_ehag516-B121","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"2026071709145309800_ehag516-B122","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1016\/j.jcmg.2018.11.002","article-title":"Correlating pathology to imaging: improved insights into peripheral artery disease?","volume":"12","author":"Arbustini","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026071709145309800_ehag516-B123","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241311123","article-title":"Multi-modality imaging of atheromatous plaques in peripheral arterial disease: integrating molecular and imaging markers","volume":"24","author":"Wang","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026071709145309800_ehag516-B124","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1161\/CIRCULATIONAHA.124.069210","article-title":"Lipoprotein(a) as a pharmacological target: premises, promises, and prospects","volume":"151","author":"Greco","year":"2025","journal-title":"Circulation"},{"key":"2026071709145309800_ehag516-B125","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ejvs.2025.05.004","article-title":"Low dose colchicine in patients with peripheral artery disease to address residual vascular risk (LEADER-PAD) trial: relevance and importance of a global initiative","volume":"70","author":"Jansen","year":"2025","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"2026071709145309800_ehag516-B126","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1089\/dia.2024.0533","article-title":"Quantitative comparison of glucagon-like peptide-1 receptor agonists on weight loss in adults: a systematic review and model-based meta-analysis","volume":"27","author":"Zhang","year":"2025","journal-title":"Diabetes Technol Ther"},{"key":"2026071709145309800_ehag516-B127","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1186\/s13287-025-04493-1","article-title":"Efficacy of autologous cell therapy on limb salvage in patients with chronic limb-threatening ischemia: 16-year single-center experience","volume":"16","author":"Sojakova","year":"2025","journal-title":"Stem Cell Res Ther"},{"key":"2026071709145309800_ehag516-B128","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1161\/ATVBAHA.122.318902","article-title":"Gene therapeutic strategies for peripheral artery disease and new opportunities provided by adeno-associated virus vectors","volume":"43","author":"Khachigian","year":"2023","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026071709145309800_ehag516-B129","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s12951-024-02603-4","article-title":"Recent advances in the use of extracellular vesicles from adipose-derived stem cells for regenerative medical therapeutics","volume":"22","author":"Yang","year":"2024","journal-title":"J Nanobiotechnology"},{"key":"2026071709145309800_ehag516-B130","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.jvs.2025.02.011","article-title":"Prescriber implementation of guideline-directed medical therapy remains poor in the peripheral artery disease population","volume":"81","author":"Minnick","year":"2025","journal-title":"J Vasc Surg"},{"key":"2026071709145309800_ehag516-B131","first-page":"910","article-title":"Prognostic relevance of female gender on mortality after peripheral artery disease revascularization","volume":"83","author":"Garagoli","year":"2023","journal-title":"Medicina (B Aires)"},{"key":"2026071709145309800_ehag516-B132","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1093\/eurjpc\/zwaf235","article-title":"Disparities in achieving low-density lipoprotein cholesterol goals after revascularization in a diverse real-world cohort","volume":"32","author":"Greenberg","year":"2025","journal-title":"Eur J Prev Cardiol"},{"key":"2026071709145309800_ehag516-B133","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1016\/j.jacc.2024.04.034","article-title":"Randomized trial of a vascular care team vs education for patients with peripheral artery disease","volume":"83","author":"Hess","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026071709145309800_ehag516-B134","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2025.102075","article-title":"Impact of a meds-to-beds PCSK9i initiation program on LDL-C in patients undergoing ASCVD revascularization","volume":"4","author":"Lorenzatti","year":"2025","journal-title":"JACC Adv"},{"key":"2026071709145309800_ehag516-B135","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ejvs.2021.05.025","article-title":"Effects of statin therapy and dose on cardiovascular and limb outcomes in peripheral arterial disease: a systematic review and meta-analysis","volume":"62","author":"Sofat","year":"2021","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"2026071709145309800_ehag516-B136","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jacc.2015.10.077","article-title":"Reduction in total cardiovascular events with ezetimibe\/simvastatin post-acute coronary syndrome: the IMPROVE-IT Trial","volume":"67","author":"Murphy","year":"2016","journal-title":"J Am Coll Cardiol"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehag516\/69166324\/ehag516.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehag516\/69166324\/ehag516.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T13:25:38Z","timestamp":1784294738000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article\/doi\/10.1093\/eurheartj\/ehag516\/8736554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":136,"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehag516","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"article-number":"ehag516"}}